Formononetin Inhibits Migration and Invasion of MDA-MB-231 and 4T1 Breast Cancer Cells by Suppressing MMP-2 and MMP-9 Through PI3K/AKT Signaling Pathways
into the blood or lymphatic vessels. The help of matrix metalloproteinases (MMPs) is required for extravasation out of the vessel, leading to the movement of cancer cells to the target tissue. Among all MMPs, MMP-2 and MMP-9, known as key enzymes in the degradation of type IV collagen, are overexpressed in breast cancer cells [ 5 , 6 ] and their elevated expression has been associated with poor prognosis [ 7 ] . Thus, MMPs could work as pivotal targets for suppressing breast cancer invasion and metastasis, and the inhibition of MMPs may have considerable advantages in cancer therapy [ 8 ] . The discovery of novel compounds with low toxicity and excellent potential for cancer chemoprevention or treatment is an important step of cancer therapy development. Formononetin (7-hydroxy-Introduction ▼ Breast cancer is the most common malignancy among women worldwide. Each year, an estimated nearly 1.4 million patients are diagnosed with breast cancer globally with more than 450 000 deaths each year [ 1 ] . Approximately 10-20 % of breast cancer cases are in the category of triple-negative phenotype, namely the absence of estrogen receptor-α, progesterone receptor, or amplifi cation of epidermal growth factor receptor [ 2 ] . Patients with triple-negative breast cancer have a very poor disease-free survival because these tumors are aggressive and associated with a high rate of metastasis compared with other types [ 3 , 4 ] . Metastasis is a multistep process, which includes detachment of cancer cells from primary tumor, migration, adhesion, and invasion of cancer cells ▼ Formononetin is a naturally existing isofl avone, which can be found in the roots of Astragalus membranaceus, Trifolium pratense, Glycyrrhiza glabra , and Pueraria lobata. It was found to be associated with inhibition of cell proliferation and cell cycle progression, as well as induction of apoptosis in various cancer cell lines. However, the eff ect of formononetin on breast cancer cell metastasis remains unclear. In this study, we examined the eff ect of formononetin on the migration and invasion of breast cancer cells MDA-MB-231 and 4T1 in vitro and in vivo. Our data demonstrated that formononetin did not eff ectively inhibit the cell viability of MDA-MB-231 and 4T1 in 24 h with the concentration lower than 160 μmol/l. When treated with nontoxic concentration of formononetin, the migration and invasion of MDA-MB-231 and 4T1 cells were markedly suppressed by wound healing assay, chamber invasion assay, and in vivo mouse metastasis model. In vitro, formononetin reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9 and increased the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2. Furthermore, the immunofluorescence and immunoblotting assays indicated that formononetin was very eff ective in suppressing the phosphorylation of Akt and PI3K. Collectively, these results suggest that formononetin inhibited breast cancer cell migration and invasion by reducing the expression of MMP-2 and MMP-9 through the PI3K/ AKT signaling pathway. These fi ndings demonstrate a potentially new therapeutic strategy of formononetin as anti-invasive agent for breast cancer. demic, antioxidant, antiviral, cardioprotective, and estrogenic activities [ 9 -15 ] . Moreover, formononetin exhibits cytotoxic activity on LNCaP and PC-3 (prostate cancer) [ 16 ] , MDA-MB-435 and MCF-7 (breast cancer) [ 17 , 18 ] , HuH-7 (live cancer) [ 19 ] , SGC-7901 (gastric cancer) [ 12 ] , as well as HeLa (cervical cancer), and HCT-116 (colon cancer) [ 20 ] cancer cell lines. Treatment of human breast cancer cells (MCF-7) with formononetin led to a signifi cant decrease in cyclin D1 protein and gene expression, which was found to be associated with IGF1/PI3K/Akt pathways [ 17 ] . In addition, numerous studies have revealed that formononetin inhibits growth in various cancer types in vivo [ 17 , 20 , 21 ] . However, it remains unclear whether formononetin will be eff ective in inhibiting breast cancer cell metastasis. MDA-MB-231 triple-negative breast cancer cell, a highly metastatic human breast carcinoma cell line, is derived from a metastatic plural eff usion fl uid and has been widely used as a model for studying breast cancer metastasis [ 22 ] . The 4T1 breast cancer cells with high propensity of metastasis were isolated from a spontaneous mammary tumor of a Balb/cC3H mouse. When these cells were transplanted into mammary pads of Balb/c mice, they formed tumors and metastasize spontaneously to tissues, such as the lung, the liver, and bones, thus providing an excellent model for examining the mechanisms of breast cancer metastasis [ 23 , 24 ] . Therefore, the objective of the study was to explore whether formononetin inhibited the migration and invasion of MDA-MB-231 and 4T1 breast cancer cells, and to further elucidate the underlying mechanism.
Materials and Methods

▼ Materials
Formononetin was purchased from Phytomarker Ltd. (Tianjin, China). It was dissolved in dimethyl sulfoxide (DMSO) and stored at 4 °C for further use. Penicillin, streptomycin, phosphate-buffered saline (PBS), trypsin-EDTA, DMEM, RPMI 1640, and fetal bovine serum (FBS) were obtained from Invitrogen (Carlsbad, CA, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 4,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma (St. Louis, MO, USA). Invasion chamber and matrigel were obtained from BD transduction Laboratories (Hercules, CA, USA). Trizol reagent, QuantiTect Reverse Transcription Kit and QuantiTect SYBR Green RT-PCR Kit were purchased from Qiagen Sciences (Germantown, MD, USA). Fluorescein isothiocyanate (FITC)-labeled secondary antibody was obtained from Invitrogen (Carlsbad, CA, USA). Antibodies against MMP-2, MMP-9, TMIP-1, TMIP-2, AKT, PI3K, ERK, JNK, phospho-AKT, phospho-PI3K, phospho-ERK, phospho-JNK, and β-actin were purchased from Cell Signaling Technology (Danvers, MA, USA). Goat anti-rabbit and goat anti-mouse peroxidase conjugated secondary antibodies were purchased from Bio-Rad (Hercules, CA, USA).
Cell culture
The human breast cancer cell line, MDA-MB-231, luciferase positive breast cancer cell (adenocarcinoma, mammary gland, further referred to as MDA-MB-231-luc) was obtained from Caliper Life Science (Hopkinton, MA, USA). Cells were cultured in DMEM medium supplemented with 10 % FBS, 1 mmol/l sodium pyruvate, 0.1 mmol/l nonessential amino acids, and antibiotics (50 IU/ ml penicillin and 50 μg/ml streptomycin) at 37 °C in a humidifi ed atmosphere of 5 % CO 2 . The media was changed every 2 or 3 days.
Cells were detached with 0.05 % trypsin-EDTA in PBS. The 4T1 cells were purchased from ATCC (Manassas, VA, USA). The cell line was cultured in RPMI 1640 medium supplemented with 10 % FBS, 2 % HEPES, 2 % sodium pyruvate, and 1 % penicillinstreptomycin antibiotic mixture. The cells were cultured according to the protocol provided by the ATCC company.
Cell growth inhibition assay
Cell viability was measured by the MTT assay. MDA-MB-231-luc and 4T1 cells were seeded into 96-well plates and cultured at a density of 5 × 10 3 cells per well. After 24 h of incubation, the cells were treated with vehicle (0.1 % DMSO) or a series of concentrations of formononetin for 24 h. MTT solution was added to each well (1.2 mg/ml) and incubated for 4 h. The concentration of MTT-formazan product dissolved in DMSO was estimated by measuring absorbance at 490 nm in an absorbance microplate reader.
Wound-healing assay
Cells were seeded in 1 × 10 5 cells/ml and grown to 80-90 % confluence in a 12-well plate at 37 °C, 5 % CO 2 incubator. The monolayers were scratched with a 10 μl sterile pipette tip, washed twice with PBS to remove fl oating cell debris, and then replaced with complete DMEM. MDA-MB-231-luc and 4T1 cells were treated with formononetin (0, 2.5, 5, 10, 20, and 40 μmol/l) and incubated for 12 h. Cell migration into the wound area was photographed under an inverted microscope. Migrated cells across the blue lines were calculated in 6 random fi elds from each triplicate treatment, and the data were presented as mean ± SD.
Cell invasion assay
The invasive abilities of MDA-MB-231-luc and 4T1 cells were tested using cell invasion chamber kit. In brief, cells were treated with various concentrations of formononetin. After 12 h, cells were detached by tryspin and resuspended in a serum-free DMEM (5 × 10 4 cells/100 μl). The cells were seeded into the upper chamber of Matrigel-coated fi lter and a DMEM or RPMI 1640 containing 10 % FBS of 500 μl was added to the lower chamber. The chamber was incubated 37 °C for 6 h. At the end of incubation, the noninvading cells in the upper surface of the fi lter membrane were carefully removed with a cotton swab. The invading cells on the lower surface of the fi lter membrane were fi xed with 4 % paraformaldehyde for 10 min and stained with crystal violet for 10 min and rinsed with water. The invasive cells on the lower surface of fi lter membrane were counted with a light microscope.
Western blot analysis
After treatment with various doses of formononetion for 12 h, the MDA-MB-231-luc and 4T1 cells were lysed with RIPA buff er containing protease and phosphatase inhibitors. The protein concentrations were measured with a BCA kit (Beyotime, China). Equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fl uoride (PVDF) membrane. The membrane was blocked with a solution containing 5 % nonfat dry milk TBST buff er (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1 % Tween 20) for 1 h. The indicated primary antibodies were incubated overnight at 4 °C, washed, and monitored by immunoblotting using a DyLight 800-conjugated secondary antibody.
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The membrane was scanned using a LI-COR Infrared Imaged Odyssey (Gene Company Limited).
Real-time quantitative PCR
MDA-MB-231-luc and 4T1 cells were treated with diff erent concentrations of formononetin for 12 h and total RNA was isolated using the Trizol reagent according to manufacturer's protocol. 
Immunofluorescence analysis
MDA-MB-231-luc cells on coverslips were washed twice with PBS and fi xed by 4 % paraformaldehyde at 4 °C for 10 min. Permeabilization of the cells was performed by incubating the cells with 0.1 % saponin and 1 % fetal bovine serum in PBS at 4 °C for 10 min. The cells were blocked with 3 % BSA at room temperature for 30 min and incubated with primary antibody against p-AKT at 4 °C overnight (0.1 % saponin and 1 % fetal bovine serum in PBS). Cells were washed twice in PBS, then incubated simultaneously with fl uorescein isothiocyanate-labeled secondary antibody for 1 h at room temperature. Negative controls were prepared by incubation of the cells with anti-IgG antibody. Nucleus was stained with DAPI for 2 min. After staining, cells were rinsed 4 times with PBS and prepared for microscopic analysis. The images were captured using an immunefluorescence microscopy (Olympus).
In vivo mouse metastasis models
All animal work was conducted in accordance with a protocol approved by the Institutional Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine. Four to six weeks old female Balb/c nude mice, purchased from Sino-British Sippr/BK Lab Animal Co, Ltd (Shanghai, China), were used for animal study. For lung metastasis study, 2 × 10 5 viable MDA-MB-231-luc breast cancer cells were resuspended in PBS and subsequently injected into the lateral tail vein in a volume of 0.1 ml. Mice were randomly divided into 3 groups: (1) vehicle (1 % DMSO in PBS) group (control), (2) low-dose formononetin group (10 mg/kg), (3) high-dose formononetin group (20 mg/kg). There were 10 mice per group. formononetin was administrated intraperitoneally (i.p.) every 2 days. Bioluminescent imaging was performed by anesthetizing and injecting mice retro-orbitally with 1.5 mg of D-luciferin (15 mg/ml in PBS), and images were acquired at 5 min after injection using the Xenogen IVIS 200 system before analysis using the Living Image software (Xenogen).
Statistical analysis
All data were presented as the means ± standard deviation (S.D.) of 3 independent experiments done in triplicate. Statistical analysis was performed by Student's t -test or one-way analysis of variance (ANOVA). Survival curves were analyzed according to the Kaplan-Meier method, and p-value was calculated for the comparisons between curves by the log-rank test. In all cases, p < 0.05 was considered statistically signifi cant.
Results
▼
Cytotoxicity of formononetin to MDA-MB-231-luc cells
Chemical structure of formononetin was shown in • ▶ Fig. 1a . To verify the eff ect of formononetin on cell viability, cells were treated with formononetin at indicated concentrations for 24 h and tested by MTT assay. Compared with untreated control cells, the viabilities of MDA-MB-231-luc and 4T1 cells were not signifi cantly aff ected by formononetin at a concentration between 0 and 80 μmol/l ( • ▶ Fig. 1b ). Furthermore, the eff ect of formononetin (0-80 μmol/l) occurred in the absence of evident cytotoxicity, as verifi ed by cell morphology ( • ▶ Fig. 1c ). Thus, noncytotoxic concentration of formononetin was used in the subsequent experiments.
Formononetin inhibited breast cancer cell migration and invasion
To investigate the inhibitory eff ect of formononetin on migration of MDA-MB-231-luc and 4T1 cells, the wound-healing assay was performed. After incubation with formononetin for 12 h, the number of cells migrated to the denuded zone was analyzed. Fig. 2a, b ). To further examine the eff ect of formononetin on the invasive ability of breast cancer cells, a BD chamber coated with matrigel was used. Our data showed that the number of cells invading the lower chamber was significantly reduced by formononetin and a 79.2 % or 78.5 % reduction in cell invasion of MDA-MB-231 or 4T1 breast cancer cell was observed for treatment with 40 mmol/l formononetin ( • ▶ Fig. 2c,   d ). These results suggest that formononetin is eff ective in preventing breast cancer cell migration and invasion.
Eff ects of formononetin on MMPs expression
Since the expression of MMPs is crucial to extracellular matrix (ECM) degradation, which is required for cell invasion, it is vital to determine whether MMPs are involved in the inhibition of migration and invasion by formononetin. The eff ects of for-mononetin on MMPs were investigated by Western blot and real time-PCR. As shown in • ▶ Fig. 3a, b , formononetin treatment led to a dose-dependent reduction in MMP-9 and MMP-2 expression. The results also demonstrated that formononetin elevated the expressions of TIMP-1 and TIMP-2, which were known to be negative regulators of MMPs. These results suggest that formononetin can aff ect expressions of proteins and genes involved in proteolytic activation.
Eff ects of formononetin on the PI3K/AKT signaling pathway
It has been reported that MMP-2 and MMP-9 expressions are critically mediated by the PI3K/Akt pathway. To investigate the eff ect of formononetin on the AKT in MDA-MB-231-luc cells, immunofl uorescence analyses were performed. The results demonstrated that formononetin inhibited the expression of the p-AKT in a concentration-dependent manner ( • ▶ Fig. 3c ). To confi rm the data generated by immunofl uorescence staining, we performed Western blot analysis of phosphorylated and total-PI3K, AKT, JNK, and ERK. Our results showed that formononetin could inhibit the expressions of p-PI3K and p-AKT in a dosedependent manner, but the levels of phospho-ERK and phos-pho-JNK were not aff ected by formononetin ( • ▶ Fig. 3d ). Taken together, all of our data suggest that formononetin suppresses the PI3K/AKT signaling pathway in breast cancer cells.
Eff ects of formononetin on lung metastasis in vivo
The mouse tail vein injection tumor metastasis model was used to evaluate the inhibitory eff ect of formononetin on MDA-MB-231-luc metastasis. After tail vein injection, vehicle control or formononetin at 10 mg/kg/day or 20 mg/kg/day was administered. Treatment continued for 35 days after MDA-MB-231-luc cells injection, and the treatment eff ect of formononetin was examined by bioluminescence imaging. As shown in • ▶ Fig. 4a, b , formononetin dramatically reduced the development of lung metastases in a dose-and time-dependent manner. Photon fl ux in the lungs of mice treated at this dose was dramatically reduced (p < 0.05 or p < 0.01) compared with control ( • ▶ Fig. 4b ).
Furthermore, survival analysis showed that mice receiving a treatment of formononetin had a statistically signifi cantly longer survival than the mice with vehicle control treatment ( • ▶ Fig. 4c ).
Discussion
▼
Recently, considerable emphases have been given to identify new anticancer agents from natural sources. Formononetin, a naturally existing isofl avone, has been reported to have a wide range of pharmacologic eff ects, such as inhibition of cell proliferation and cell cycle progression, and induction of apoptosis in various cancer cell lines [ 12 , 16 -20 , 25 ] . Metastatic spread of breast cancer is responsible for 90 % of human cancer-related deaths and thus remains one of the important negative predictors of breast cancer prognosis [ 26 , 27 ] . However, whether formononetin exerts an inhibitory eff ect on breast cancer metastasis has not been elucidated previously.
In the present study, we have demonstrated that formononetin strikingly inhibited the migratory and invasive abilities of breast cancer cells at noncytotoxic concentrations in vitro ( • ▶ Fig. 2 ).
These results indicated that formononetin inhibited breast cancer cell migration and invasion, and the eff ect was not attributed to its cytotoxicity. In addition, we also found that formononetin inhibited breast cancer cell metastasis and prolonged animal survival time in vivo ( • ▶ Fig. 4 ). These results indicated that formononetin might play a benefi cial role in breast cancer metastasis. A vital step in cancer metastasis processes is the proteolytic degradation of the ECM by proteolytic enzymes, such as MMPs [ 28 ] .
MMPs are a family of zinc-containing endopeptidases, of which MMP-2 and MMP-9 are highly expressed in aggressive breast tumors and are associated with poor clinical outcome [ 5 , 6 , 29 , 30 ] . The inhibition of MMP-2 and MMP-9 expressions is a critical step in the prevention of cancer metastasis [ 27 , 31 -33 ] . TIMPs, the regulators of MMPs, are also involved in tumor progression, invasion, metastasis and angiogenesis [ 34 ] . Furthermore, increased expressions of TIMP-1 or TIMP-2 have been shown to suppress cell invasion [ 35 -37 ] . In our study, it was found that the inhibition of MMP-2 and MMP-9 expressions and the increase in TIMP-1 and TIMP-2 expressions were attributable to the anti-invasive eff ect of formononetin ( • ▶ Fig. 3a, b ).
Many have reported that MMP-2 and MMP-9 expression were mediated by the PI3K/Akt pathway [ 38 -43 ] . PI3K is a lipid kinase that controls multiple cellular processes through AKT activation. Furthermore, AKT activation can lead to cancer invasion and metastasis by stimulating the secretion of MMPs [ 39 , 44 , 45 ] . The presence of phosphatidylinositol 3-kinase γ (PI3Kγ) overexpression is characteristic in the metastatic breast cancer cells, when compared with the normal breast epithelial cell line or nonmetastatic breast cancer cells. In addition, the overexpression of recombinant PI3Kγ was reported to be able to increase the metastatic ability of nonmetastatic breast cancer cells [ 46 ] . Moreover, PI3K inhibitor could lead to a reduction in MMP-2 activation, cell migration and cell invasion [ 47 ] . Some traditional Chinese medicine monomers and compounds have been reported to have inhibitory eff ects on the migration and invasion of cancer cells via reducing the expression of MMPs via the PI3K/Akt signaling pathway [ 48 -56 ] . It was also reported that formononetin inhibited the breast cancer cell proliferation by decreasing the expression of cyclin D1 via the IGF1/PI3K/Akt pathways [ 17 ] . In our study, we have demonstrated that treatment with formononetin signifi cantly reduced PI3K and Akt phosphorylation ( • ▶ Fig. 3c, d ), which indicated an inhibitory eff ect to the PI3K/ Akt signaling pathway by formononetin. Therefore, we suggest that formononetin inhibits the invasion of breast cancer cells by reducing the expression of MMP-2 and MMP-9 through PI3K/Akt signaling pathways.
In conclusion, the present study has demonstrated that formononetin decreased the invasive ability of MDA-MB-231 and 4T1 breast cancer cells, including migration and invasion, by inhibiting MMP-2 and MMP-9 expressions. This eff ect might be attributed to the inactivation of PI3K/Akt pathway. These results provide new insights into molecular mechanisms involved in the anti-invasive activity of formononetin in breast cancer cells. This fi nding strongly suggests formononetin to be a potentially useful anti-invasive agent for breast cancers.
